Skip to Main Content Go to Sitemap

Sylvain Baruchel

Title:
Senior Medical Advisor, Innovative Therapies
Designations:
MD
Phone:
416-813-7795
Email:
Sylvain.baruchel@sickkids.ca
Alternate Contact Name:
Catherine Lim-Shue
Alternate Phone:
416-813-7654 ext. 228454
Alternate Email:
Catherine.limshue@sickkids.ca
U of T Positions:
Professor Emeritus, Department of Paediatrics

Research Positions

Emeritus Senior Associate Scientist
Translational Medicine

Biography

Dr. Baruchel is a leader in Oncology clinical trials at The Hospital for Sick Children (SickKids), acting as the director of the Clinical Trial Program for 20 years and is the founder of the New Agent and Innovative Therapy Program. Dr. Baruchel is nationally and internationally recognized for his work in oncology drug development. He is the founder and former chair of the Canadian C17 Developmental Therapeutic Network, and former chair of the National Cancer Institute of Canada Paediatric Investigational New Drug committee. 

He is currently the Senior Medical Advisor for Innovative Therapies, where he advises the Department of Paediatric’s Chair and Chair of SickKids Research Institute on matters related to innovative therapeutics. Dr. Baruchel collaborates with Dr. Rulan Parekh, the Associate Chair of Clinical Research, in leading and developing the infrastructure and processes needed to implement and conduct SickKids-sponsored innovative therapeutic trials using novel agents, or devices at SickKids. His mandate within the Clinical Research Secretariat is to advise the co-chair on clinical research and to develop a pipeline committee and efforts to streamline translational research and clinical trials. He acts as a resource for the Hospital and Research Institute Principal Investigators looking at early phase trial development.

Dr. Baruchel is also a paediatric expert consultant for Canadian Agency for Drugs and Technologies in Health (CADTH). He represents SickKids Research Institute on the Ted Rogers Heart Research Centre’s translational and commercialization committee.

Back to Top